Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
VORANIGO (VORASIDENIB) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
VORANIGO
NDA
Get alerts
VORASIDENIB | N218784 | SERVIER PHARMACEUTICALS LLC
2 strengths
5 unique patents
2 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
5 unique patents, 2 exclusivities by expiration date
All strengths
10MG
40MG
Active (5)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
Today
9579324
Jul. 11, 2034
10172864
Jul. 11, 2034
11345677
Jan. 16, 2039
11844758
Dec. 4, 2035
12433895
Jul. 11, 2034
NCE
Aug. 6, 2029
ODE-491
Aug. 6, 2031
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 10MG
RLD
5 patents
2 exclusivities
▴
TABLET;ORAL | Approved: Aug 6, 2024
Patents (5)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
9579324
Jul 11, 2034
—
Yes
—
—
—
10172864
Jul 11, 2034
—
Yes
Yes
—
—
11345677
Jan 16, 2039
—
Yes
Yes
U-3978
A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 OR IDH2 MUTATION OR COMBINATION THEREOF FOLLOWING SURGERY, WHEREIN THE CANCER IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA
—
11844758
Dec 4, 2035
—
—
—
U-3977
A METHOD OF TREATING A GLIOMA CHARACTERIZED BY AN IDHI MUTATION FOLLOWING SURGERY, WHEREIN THE GLIOMA IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA
—
12433895
Jul 11, 2034
—
—
—
U-4286
A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION FOLLOWING SURGERY, WHEREIN THE CANCER IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA
—
Exclusivities (2)
Code
Date
Status
NCE
Aug 6, 2029
Active
ODE-491
Aug 6, 2031
Active
#002 — 40MG
RLD
5 patents
2 exclusivities
▾
TABLET;ORAL | Approved: Aug 6, 2024